Subscribe
Israel-Hamas Conflict
Election Day
Donald Trump
Fox News
Kamala Harris
US Economy
US Politics
Volleyball
Republican Party
US Immigration
Abortion
Women's Rights
US Crime
Published

RE104 aims to become the first psychedelic to treat postpartum depression

Summary by contemporaryobgyn.net
Reunion Neuroscience is enrolling patients in its phase 2 RECONNECT trial to assess a single-dose synthetic psychedelic to treat the depressive symptoms of PPD.
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

PsychedelicPsychedelic
San DiegoSan Diego

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

Trending Topics
Ground News logo
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc
News
For You
Search
BlindspotLocal